Apalutamide (Erleada) is indicated for the treatment of patients with: metastatic castration-sensitive prostate cancer (mCSPC); non-metastatic, castration-resistant prostate cancer (nmCRPC).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education